Discussion
Treatment with the approved Dravet syndrome drug Fintepla (fenfluramine) was more effective than a placebo at reducing seizure frequency and extending periods without seizures among a diverse group of children and adolescents with the rare disease, data from three late-stage clinical trials show. The oral therapy, widely cleared…